Huang Yen-Wei, Lee Chun-Ting, Wang Ta-Chen, Kao Yun-Chung, Yang Chih-Hui, Lin Yu-Mei, Huang Keng-Shiang
The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.
Department of Chinese Medicine, E-DA Hospital, Kaohsiung, Taiwan.
Curr Protein Pept Sci. 2018;19(10):998-1010. doi: 10.2174/1389203719666180531122724.
Dengue fever has become an imminent threat to international public health because of global warming and climate change. The World Health Organization proclaimed that more than 50% of the world's population is at risk of dengue virus (DENV) infection. Therefore, developing a clinically approved vaccine and effective therapeutic remedy for treating dengue fever is imperative. Peptide drug development has become a novel pharmaceutical research field. This article reviews various peptidesbased antimicrobial agents targeting three pathways involved in the DENV lifecycle. Specifically, they are peptide vaccines from immunomodulation, peptide drugs that inhibit virus entry, and peptide drugs that interfere with viral replication. Many antiviral peptide studies against DENV have been conducted in animal model trials, and progression to clinical trials for these promising peptide drugs is anticipated.
由于全球变暖和气候变化，登革热已成为对国际公共卫生的紧迫威胁。世界卫生组织宣称，全球超过50%的人口有感染登革热病毒（DENV）的风险。因此，开发一种临床批准的疫苗和有效的登革热治疗药物势在必行。肽类药物开发已成为一个新的药物研究领域。本文综述了针对登革热病毒生命周期中三个途径的各种基于肽的抗菌剂。具体而言，它们是来自免疫调节的肽疫苗、抑制病毒进入的肽药物以及干扰病毒复制的肽药物。许多针对登革热病毒的抗病毒肽研究已在动物模型试验中进行，预计这些有前景的肽药物将进入临床试验阶段。
